Clinical Research Directory

Inclusion Criteria: * Age 18-64 years (both inclusive) at the time of signing the informed consent. * Male or female (sex assigned at birth, inclusive of all gender identities). * Body mass index (BMI) between 30.0 - 44.9 kilogram per meter square (kg/m\^2) (both inclusive) at screening. Obesity should be due to excess adipose tissue, as judged by the investigator. Exclusion Criteria: * Known or suspected hypersensitivity to study intervention(s) (including paracetamol) or related products. * Use of prescription medicinal products or non-prescription drugs, including any herbal medicine known to interfere with the metabolic CYP pathways, such as perikon (St. John's Wort), within 14 days (or within 5 half-lives of the medicinal product, whichever is longest) of screening, with the exception of use of routine vitamins (vitamins used within a normal dose reference interval) and occasional use of paracetamol/acetaminophen, ibuprofen and acetylsalicylic acid, or topical medication not reaching systemic circulation. * Impaired liver function defined as any of the below: 1. Alanine Aminotransferase (ALT) greater than or equal to (\>= ) 2.5 times the upper limit of normal (ULN) 2. Aspartate Aminotransferase (AST) \>=2.5 times ULN 3. Total bilirubin greater than (\>) 1.5 times ULN